Congenital Adrenal Hyperplasia

Overview of Congenital Adrenal Hyperplasia

• Congenital adrenal hyperplasia (CAH) encompasses a family of autosomal recessive disorders characterized by genetic defects in the enzymes required for cortisol biosynthesis.
• The fundamental pathophysiology shared by these disorders involves insufficient cortisol production, which eliminates normal negative feedback inhibition on the hypothalamus and pituitary gland.
• The resulting hypersecretion of corticotropin (ACTH) drives continuous stimulation of the adrenal cortex, leading to adrenocortical hyperplasia and the massive accumulation of intermediate steroid metabolites proximal to the enzymatic block.
• Depending on the specific enzyme deficiency, these accumulated precursors are shunted into alternative open pathways, resulting in characteristic patterns of mineralocorticoid deficiency or excess, as well as varying degrees of androgen deficiency or excess.
• Clinical phenotypes range from fatal neonatal salt-wasting crises and ambiguous genitalia to delayed puberty, hypertension, and asymptomatic nonclassic forms presenting in adulthood.

Summary Table of Congenital Adrenal Hyperplasia Types

21-Hydroxylase Deficiency (CYP21A2)

Epidemiology and Genetics

• 21-hydroxylase deficiency is the most common form of CAH, accounting for 90% to 95% of all cases.
• The incidence of classic forms is estimated to be between 1 in 14,000 and 1 in 18,000 births, varying significantly among different racial and ethnic backgrounds.
• The disorder is caused by mutations in the CYP21A2 gene, which is located on the short arm of chromosome 6 (6p21.3) within the highly complex human leukocyte antigen (HLA) class III region.
• CYP21A2 is located adjacent to a highly homologous pseudogene (CYP21A1P); mispairing during meiosis leads to gene deletions or the transfer of deleterious mutations from the pseudogene to the active gene (gene conversions).

Pathophysiology

• Decreased 21-hydroxylase activity impairs the conversion of 17-OHP to 11-deoxycortisol in the zona fasciculata, drastically reducing cortisol biosynthesis.
• Concurrently, the conversion of progesterone to deoxycorticosterone (DOC) in the zona glomerulosa is impaired, preventing the synthesis of aldosterone.
• The massive accumulation of 17-OHP is shunted into the androgen biosynthesis pathway, leading to excess production of androstenedione and testosterone.
• Elevated 17-OHP also activates alternative androgenic routes, specifically the "backdoor pathway" to dihydrotestosterone (DHT), which bypasses traditional intermediates and contributes significantly to prenatal virilization in affected females.
• Additionally, 11-oxygenated C-19 steroids (such as 11-ketotestosterone), derived from the action of 11β-hydroxylase on androstenedione and testosterone, represent major circulating bioactive androgens in 21-hydroxylase deficiency.

Clinical Presentation

• Classic Salt-Wasting Form: Occurs in approximately 70% of classic cases, characterized by complete or near-complete lack of enzymatic activity (0-2% of normal). Patients suffer from profound glucocorticoid and mineralocorticoid deficiency, presenting in the first weeks of life with life-threatening hyponatremia, hyperkalemia, hypovolemia, acidosis, and shock.
• Classic Simple Virilizing Form: Accounts for about 30% of classic cases, where patients retain roughly 1% to 2% of enzymatic activity. This trace activity produces sufficient aldosterone to prevent frank salt-wasting crises, though plasma renin activity is often elevated, indicating a compensated state.
• Female Genital Ambiguity: 46,XX infants with classic forms present at birth with varying degrees of virilization, including clitoromegaly, partial or complete fusion of the labioscrotal folds, and a single urogenital sinus opening. Internal Müllerian structures (uterus, fallopian tubes) remain completely normal because these patients lack anti-Müllerian hormone (AMH).
• Male Presentation: 46,XY infants have completely normal male external genitalia at birth. Without newborn screening, boys with the simple virilizing form may evade detection until early childhood when they present with rapid somatic growth, premature pubarche, enlarged penis, but small prepubertal testes (indicating peripheral, gonadotropin-independent precocity).
• Nonclassic Form: Caused by mutations (e.g., V281L) retaining 20% to 50% of normal enzyme activity. Patients are asymptomatic at birth with normal genitalia. They later present in childhood or adolescence with premature adrenarche, acne, hirsutism, menstrual irregularities, or infertility.

Diagnosis and Newborn Screening

• The diagnosis of 21-hydroxylase deficiency is confirmed by detecting highly elevated concentrations of serum 17-OHP.
• In classic affected neonates, baseline 17-OHP levels typically exceed 10,000 ng/dL (300 nmol/L).
• For nonclassic or milder cases, an ACTH stimulation test is the definitive diagnostic tool; an exaggerated rise in 17-OHP at 60 minutes confirms the defect.
• Newborn screening programs utilizing dried blood spots on filter paper measure 17-OHP to identify classic CAH and prevent fatal salt-wasting crises.
• False-positive newborn screens are common, particularly in premature infants, stressed neonates, or heterozygote carriers; samples collected before 48 hours of life can also reflect the physiologic postnatal surge of 17-OHP.
• Second-tier testing utilizing liquid chromatography-tandem mass spectrometry (LC/MS/MS) on the newborn screen significantly improves specificity by eliminating cross-reacting steroids.

11β-Hydroxylase Deficiency (CYP11B1)

Pathophysiology and Genetics

• This disorder accounts for 3% to 5% of all CAH cases but is notably more frequent among Moroccan Jews (incidence approximating 1 in 6,000).
• It is caused by mutations in the CYP11B1 gene on chromosome 8q24.3, which encodes the enzyme responsible for converting 11-deoxycortisol to cortisol in the zona fasciculata.
• The blockade causes ACTH-driven accumulation of 11-deoxycortisol and, importantly, DOC.
• DOC possesses potent mineralocorticoid activity; its massive accumulation causes salt and water retention, suppressing the renin-angiotensin-aldosterone system.

Clinical Presentation

• Androgen Excess: Affected 46,XX fetuses present with ambiguous, virilized external genitalia similar to those with 21-hydroxylase deficiency. Postnatally, both sexes experience rapid somatic growth, advanced skeletal maturation, and premature virilization.
• Hypertension: The hallmark of 11β-hydroxylase deficiency is hypertension accompanied by hypokalemic alkalosis, caused by the prolonged exposure to excessive DOC.
• Despite overall mineralocorticoid excess, infants may paradoxically experience transient salt loss in the neonatal period due to severe mineralocorticoid receptor blockade by other accumulated precursors.

Diagnosis

• Biochemically characterized by markedly elevated serum 11-deoxycortisol and DOC levels, both at baseline and following ACTH stimulation.
• Serum 17-OHP and androgens (androstenedione, testosterone) are moderately elevated, while plasma renin activity (PRA) is classically suppressed.

3β-Hydroxysteroid Dehydrogenase Type 2 Deficiency (HSD3B2)

Pathophysiology and Genetics

• Caused by mutations in the HSD3B2 gene mapped to chromosome 1p12, encoding an enzyme necessary for multiple steroidogenic branches.
• The enzyme catalyzes the conversion of Δ5-steroids (pregnenolone, 17-hydroxypregnenolone, and DHEA) into Δ4-ketosteroids (progesterone, 17-OHP, and androstenedione).
• Deficiency impairs the synthesis of all three classes of adrenal steroids: glucocorticoids, mineralocorticoids, and active gonadal sex steroids.

Clinical Presentation

• Adrenal Crisis: Most patients present with severe salt-wasting and adrenal insufficiency in early infancy.
• Genital Ambiguity in Both Sexes: This is a unique feature of HSD3B2 deficiency.
• 46,XY Infants: Present with incomplete masculinization (hypospadias, bifid scrotum, cryptorchidism) because the testes cannot convert DHEA to potent androgens (testosterone and DHT) efficiently.
• 46,XX Infants: Present with mild virilization (clitoromegaly) driven by the massive overproduction of the weak androgen DHEA, which is peripherally converted into active androgens by the intact type 1 3β-HSD enzyme present in the liver and skin.

Diagnosis

• Diagnostic hormonal profile shows markedly elevated levels of Δ5-steroids, primarily 17-hydroxypregnenolone and DHEA, with a characteristically high ratio of Δ5 to Δ4 steroids following an ACTH stimulation test.

17α-Hydroxylase / 17,20-Lyase Deficiency (CYP17A1)

Pathophysiology and Genetics

• Accounts for less than 1% of CAH cases and is caused by mutations in CYP17A1 located on chromosome 10q24.3.
• The CYP17A1 enzyme performs two distinct reactions: 17α-hydroxylation (essential for cortisol and sex steroids) and 17,20-lyase activity (essential for producing DHEA and androstenedione, the precursors to testosterone and estradiol).
• The complete enzyme blockade eliminates cortisol and sex steroid production, shifting all steroidogenic precursors into the mineralocorticoid pathway (DOC and corticosterone).

Clinical Presentation

• Hypertension: The unchecked accumulation of DOC causes severe hypertension and hypokalemic alkalosis with suppressed renin and aldosterone.
• Sexual Infantilism / DSD: Because sex steroid synthesis is abolished in both the adrenals and gonads:
  • 46,XY Infants: Present with completely female external genitalia or severe ambiguity (undervirilization) due to the absence of fetal testosterone.
  • 46,XX Infants: Present with normal female external genitalia at birth but completely fail to undergo puberty (primary amenorrhea and absent secondary sexual characteristics) due to the lack of estrogen production.

Diagnosis

• Laboratory testing reveals elevated levels of DOC and corticosterone, alongside suppressed levels of 17-OHP, cortisol, androgens, and estrogens. Gonadotropins (LH and FSH) are elevated in pubertal-aged patients.

Congenital Lipoid Adrenal Hyperplasia

Pathophysiology and Genetics

• This represents the most profound and severe form of CAH, leading to the disruption of all steroidogenesis (glucocorticoids, mineralocorticoids, and sex steroids).
• It is primarily caused by mutations in the STAR gene (8p11.2), which encodes the Steroidogenic Acute Regulatory protein required to transport free cholesterol from the outer to the inner mitochondrial membrane.
• The Two-Hit Model: In early gestation, StAR-independent pathways allow for trace steroidogenesis (approximately 14% of normal). The resulting cortisol deficiency triggers massive ACTH release, driving extreme cellular uptake of cholesterol. The accumulating cholesterol esters physically destroy the cellular architecture and induce chemical toxicity (auto-oxidation), irreversibly obliterating all steroidogenic capacity (the "second hit").
• Alternatively, an identical phenotype is caused by mutations in CYP11A1 (P450 side-chain cleavage enzyme), which prevents the direct conversion of cholesterol into pregnenolone.

Clinical Presentation

• Infants typically present with severe, life-threatening acute adrenal crisis and profound salt-wasting shortly after birth.
• Due to the destruction of fetal Leydig cells or the inability to synthesize testosterone, affected 46,XY genetic males are born with entirely female external genitalia and a blind vaginal pouch.
• Müllerian structures (uterus, tubes) are absent in 46,XY patients because the undamaged Sertoli cells continue to secrete AMH.
• In STAR mutations, the adrenal glands are massively enlarged and engorged with lipids; conversely, in CYP11A1 mutations, the adrenal glands appear normal or small on ultrasound.

Cytochrome P450 Oxidoreductase (POR) Deficiency

Pathophysiology and Genetics

• A complex and relatively recently defined variant of CAH caused by mutations in the POR gene on chromosome 7q11.2.
• POR is an essential flavoprotein that donates electrons to all microsomal cytochrome P450 enzymes, directly impacting the function of 21-hydroxylase, 17α-hydroxylase, and aromatase.
• The varied impairment across multiple enzymes creates a uniquely mixed biochemical and clinical profile.

Clinical Presentation

• Genital Ambiguity: Manifests in both genetic sexes. 46,XX females are virilized (partly due to the utilization of the alternative backdoor pathway to DHT), while 46,XY males are undervirilized due to combined 17α-hydroxylase/17,20-lyase impairment.
• Maternal Virilization: Pregnant mothers carrying an affected fetus may experience progressive virilization during gestation because the mutant placental aromatase fails to convert abundant fetal androgens into estrogens.
• Skeletal Dysplasia: POR deficiency is strongly associated with the Antley-Bixler syndrome phenotype, characterized by severe skeletal anomalies including craniosynostosis, midface hypoplasia, radiohumeral synostosis, and bowing of the femora.

Management of Congenital Adrenal Hyperplasia

Pharmacological Therapy

• Glucocorticoid Replacement: The primary goal is to replace deficient cortisol and suppress the excessive ACTH drive, thereby mitigating adrenal androgen overproduction. Oral hydrocortisone is the preferred therapy in growing children to minimize the risk of growth suppression.
• Mineralocorticoid Replacement: Patients with salt-wasting forms strictly require fludrocortisone to maintain sodium balance, prevent hyperkalemia, and normalize plasma renin activity.
• Sodium Supplementation: Infants require oral sodium chloride supplementation because the infant diet (breast milk or formula) is naturally low in sodium.

Surgical Considerations and Gender Rearing

• Decisions regarding the sex of rearing and the timing of genitoplasty in severely virilized 46,XX infants are complex and require a multidisciplinary approach encompassing endocrinologists, urologists, and psychologists.
• 46,XX individuals with CAH possess normal internal reproductive organs (ovaries and uterus) and retain full potential for future fertility; the vast majority are raised as females and identify with the female gender.
• Surgical correction (e.g., clitoroplasty and vaginoplasty) is highly individualized, and current paradigms weigh the benefits of early anatomical correction against the risks of long-term sexual dysfunction and the child's future autonomy.

Long-Term Monitoring

• The adequacy of therapy must be routinely monitored by tracking the child's linear growth velocity and skeletal maturation (bone age).
• Biochemical monitoring focuses on finding a balance: measuring androstenedione and testosterone to ensure adequate androgen suppression, while using 17-OHP to guard against the overtreatment and resultant iatrogenic Cushing syndrome.
• Plasma renin activity (PRA) is monitored to gauge the precise adequacy of mineralocorticoid and sodium replacement.
• In adolescent and adult males with CAH, routine testicular ultrasound screening is mandated to detect testicular adrenal rest tumors (TARTs), which are driven by chronic ACTH excess and can cause irreversible infertility.